Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 50 of 65 Next >>

Filter Applied: interferon (Click to remove)

A 29-Year-Old Man with Multiple Sclerosis
JAMA 280:1432-1439, Rudick,R.A., 1998

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 373:1418-1428, Kappos, L.,et al, 2015

Interferon beta for Secondary Progressive Multiple Sclerosis: A Systematic Review
JNNP 84:420-426, La Mantia, L.,et al, 2013

Association Between Immediate Initiation of Intramuscular Interferon Beta-1a at the Time of a Clinically Isolated Syndrome and Long-term Outcomes
Arch Neurol 69:183-190, Kinkel,R.P.,et al, 2012

Interferon �-Associated Retinopathy in Patients Treated for Multiple Sclerosis
Neurol 70:1153-1155, Folden,D.V.,et al, 2008

Combining Beta Interferon and Atorvastatin May Increase Disease Activity in Multiple Sclerosis
Neurol 71:1390-1395,1386, Birnbaum,G.,et al, 2008

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008

Neutralizing Antibodies to Interferon Beta: Assessment of Their Clinical and Radiographic Impact: An Evidence Report
Neurol 68:977-984, Goodin,D.S.,et al, 2007

Effect of Early Verus Delayed Interferon Beta-1b Treatment on Disability After a First Clinical Event Suggestive of Multiple Sclerosis: A 3-Year Follow-Up Analysis of the BENEFIT Study
Lancet 370:389-397, Kappos,L.,et al, 2007

How Effective Are Disease-Modifying Drugs in Delaying Progression in Relapsing-Onset MS?
Neurol 69:1498-1507, Brown,M.G.,et al, 2007

Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006

Interferon beta-1a Treatment in Childhood and Juvenile-Onset Multiple Sclerosis
Neurol 67:511-513, Tenembaum,S.N. &Segura,M.J., 2006

Treatment of Early Onset Multiple Sclerosis With Subcutaneous Interferon Beta-1a
Neurol 64:888-890, 778, Pohl,D., et al, 2005

Liver Injury Associated with the B-Interferons for MS
Neurol 62:628-631, Tremlett,H.L.,et al, 2004

Clinical Implications of Benign Multiple Sclerosis: A 20-Year Population-Based Follow-Up Study
Ann Neurol 56:303-306, Pittock,S.J.,et al, 2004

Interferons in Relapsing Remitting Multiple Sclerosis: A Systematic Review
Lancet 361:545-552, Filippini,G.,et al, 2003

Recombinant Interferon-a-induced Chorea and Frontal Subcortical Dementia
Neurol 58:328-330, Moulignier,A.,et al, 2002

Interferon Beta but not Glatiramer Acetate Therapy Aggravates Headaches in MS
Neurol 59:636-639, Pollmann,W.,et al, 2002

Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management
The Neurologist 8:227-236, Frohman,E.,et al, 2002

Effect of Early Interferon Treatment on Conversion to Definite Multiple Sclerosis: A Randomised Study
Lancet 357:1576-1582,1547, Comi,G.,et al, 2001

Fulminant Liver Failure During Interferon Beta Treatment of Multiple Sclerosis
Neurol 56:1416, Yoshida,E.M.,et al, 2001

Randomized Controlled Trial of Interferon-beta-1a in Secondary Progressive MS
Neurol 56:1496-1504, Secondary Progressive Efficacy Clinical Trial of R, 2001

PRISMS-4: Long-Term Efficacy of Interferon-B-1a in Relapsing MS
Neurol 56:1628-1636,1620, The PRISMS Study Group, 2001

Multiple Sclerosis--From Probable to Definite Diagnosis
Arch Neurol 57:974-979,930, Achiron,A. & Barak,Y., 2000

Relapses and Progression of Disability in Multiple Sclerosis
NEJM 343:1430-1438,1486, Confavreux,C.,et al, 2000

Multiple Sclerosis,Therapeutic Update
Arch Neurol 56:277-280, Tselis,A.C.&Lisak,R.P., 1999

Severe Anaphylaxis with Recombinant Interferon Beta
Neurol 52:425, Corona,T.,et al, 1999

Ibuprofen Treatment Versus Gradual Introduction of Interferon B-1b in patients with MS
Neurol 52:1893-1895, Rice,G.P.A.,et al, 1999

Evidence of Interferon B-1a Dose Response In Relapsing-Remitting MS, The OWIMS Study
Neurol 53:679-686, The Once Weekly Interferon for MS Study Group (OWI, 1999

Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics
Arch Neurol 56:1079-1084, Rudick,R.A., 1999

Multiple Sclerosis, Side Effects of Interferon Beta Therapy and Their Management
Neurol 53:1622-1627, Walther,E.U.&Hohlfeld,R., 1999

Interferon Treatment for Multiple Sclerosis:Autoimmune Complications May be Lethal
Neurol 50:570-571, Durelli,L.,et al, 1998

Rate of Pregnancy-Related Relapse in Multiple Sclerosis
NEJM 339:285-291, 3391998., Confavreux,C.,et al, 1998

Clinicopath Conf
Subacute Sclerosing Panencephalitis, Case 15-1998, NEJM 338:1448-1456998., , 1998

Spastic Diplegia as a Complication of Interferon Alfa-2a Treatment of Hemangiomas of Infancy
J Pediatr 132:527-530, Barlow,C.F.,et al, 1998

Randomised Double-Blind Placebo-Controlled Study of Interferon B-1a in Relapsing/Remitting Multiple Sclerosis
Lancet 352:1498-1504,1486, PRISMS, 1998

Current Immunotherapy in Multiple Sclerosis
Immunology and Cell Biology 76:55-64, Bashir,K.&Whitaker,J.N., 1998

Long-Term Follow-up of Pts with SSPE Treated with Intraventricular alpha-Interferon
Neurol 48:526-528, Anlar,B.,et al, 1997

Drugs and Myasthenia Gravis, An Update
Arch Int Med 157:399-408, Wittbrodt,E.T., 1997

Impact of Interferon Beta-1A On Neurologic Disability in Relapsing Multiple Sclerosis
Neurol 49:358-363, Rudick,R.A.,et al, 1997

Anticytokine Antibodies in Beta Interferon-Trated MS Patients and the Need for Testing
Neurol 49:647-650, Pachner,A.R., 1997

The Quality-of-Life Effects of Interferon Beta-1b in MS
Arch Neurol 54:1475-1480, Schwartz,C.E.,et al, 1997

Management of Multiple Sclerosis
NEJM 337:1604-1611, Rudick,R.A.,et al, 1997

Management of Patients Receiving Interferon Beta-1b for MS:Report of a Consensus Conf
Neurol 46:12-18, Lublin,F.D.,et al, 1996

Side Effect Profile of Interferon Beta-1b in MS:Results of an Open Label Trial
Neurol 46:552-554, Neilley,L.K.,et al, 1996

Progressive Multifocal Leukoencephalopathy:Clinical and MR Response to Treatment
AJNR 17:597-600, Garrels,K.,et al, 1996

Neutralizing Antibodies During Treatment of Multiple Sclerosis with Interferon Beta-1b
IFNB MS Study Group & UBC MS. MRI Analysis Group, Neurol 47:889-8946., , 1996

Guidelines for Physicians with Patients on IFNB-1b:The Use of an Assay for Neutralizing Antibodies (NAB)
Neurol 47:865-866, Paty,D.,et al, 1996

The Interferons:Biological Effects, Mechanisms of Action, and Use in Multiple Sclerosis
Ann Neurol 37:7-15, Weinstock-Guttman,B.,et al, 1995



Showing articles 0 to 50 of 65 Next >>